Overview of FCS

Author(s):

Peter Toth, MD, PhD, FCCP, FESC, FAHA, FACC ,James Underberg, MS, MD, FACP, FACPM, FASPC, FASH, FNLA

Key Takeaways

Familial Chylomicronemia Syndrome is genetically confirmed, while Persistent Chylomicronemia is often clinically diagnosed due to secondary factors.
FCS prevalence in the US is about 1-2 per million, with significant disease burden including recurrent pancreatitis.
Signs of FCS include severe hypertriglyceridemia, abdominal pain, and eruptive xanthomas, with diagnosis confirmed by genetic testing.
Differentiation from other hyperlipidemias involves genetic testing and evaluating triglyceride response to dietary fat restriction.

Panelists discuss how familial chylomicronemia syndrome (FCS) and persistent chylomicronemia are diagnosed either genetically or clinically, outlining the prevalence and disease burden of FCS in the US, as well as its signs, symptoms, and diagnostic criteria, and how to differentiate FCS from other forms of hyperlipidemia.

Now Viewing

EP: 1.Overview of FCS

EP: 2.Severe Hypertriglyceridemia

Video content above is prompted by the following:

Please provide an overview of Familial Chylomicronemia Syndrome, or FCS, and Persistent Chylomicronemia. (please note which is genetically confirmed vs clinically diagnosed and; expand on them two).
- What is the prevalence and disease burden of FCS in the United StatesUS?
What are the signs/symptoms and diagnostic criteria of FCS?

How do you differentiate FCS from other forms of hyperlipidemia?